<code id='84E23C76B2'></code><style id='84E23C76B2'></style>
    • <acronym id='84E23C76B2'></acronym>
      <center id='84E23C76B2'><center id='84E23C76B2'><tfoot id='84E23C76B2'></tfoot></center><abbr id='84E23C76B2'><dir id='84E23C76B2'><tfoot id='84E23C76B2'></tfoot><noframes id='84E23C76B2'>

    • <optgroup id='84E23C76B2'><strike id='84E23C76B2'><sup id='84E23C76B2'></sup></strike><code id='84E23C76B2'></code></optgroup>
        1. <b id='84E23C76B2'><label id='84E23C76B2'><select id='84E23C76B2'><dt id='84E23C76B2'><span id='84E23C76B2'></span></dt></select></label></b><u id='84E23C76B2'></u>
          <i id='84E23C76B2'><strike id='84E23C76B2'><tt id='84E23C76B2'><pre id='84E23C76B2'></pre></tt></strike></i>

          Home / comprehensive / focus

          focus


          focus

          author:explore    Page View:41
          Adobe

          LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

          The deal includes up to another $400 million in payments if certain milestones are met.

          advertisement

          Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In